Wandercraft筹集 7500万美元资金，推出自我平衡外骨骼装置-动脉网

Wandercraft raises $75m in funding to introduce self-balancing exoskeleton

Medical Device Network 等信源发布 2025-06-12 10:34



可切换为仅中文







The funding is intended to support the company’s robotic exoskeleton technologies. Credit: Gorodenkoff / Shutterstock.

这笔资金旨在支持该公司的机器人外骨骼技术。图片来源：Gorodenkoff / Shutterstock。

Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026.

机器人公司Wandercraft在D轮融资中筹集了7500万美元，计划到2026年将自平衡个人外骨骼Eve推向市场。

This investment will fuel the company’s growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance.

这笔投资将推动公司的成长，并加速其旗舰康复系统 Atalante X 的扩展，该系统已获得 FDA 批准。

Go deeper with GlobalData

深入探索GlobalData

Reports

报告

Balloon Sinuplasty Systems Market Size (Value, Volume, ASP) by Segm...

气球鼻窦成形术系统市场规模（价值、数量、平均售价）按细分市场...

Reports

报告

Cloud in Healthcare: Wearable Fitness Monitors

医疗领域的云技术：可穿戴健身监测器

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

After receiving second clearance, Atalante X’s use was expanded to US hospitals and clinics.

在获得第二次批准后，Atalante X 的使用范围扩大到了美国的医院和诊所。

It will also support the development and deployment of Calvin-40, Wandercraft’s humanoid robot.

它还将支持Wandercraft的人形机器人Calvin-40的开发和部署。

The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others.

D轮融资轮次中，雷诺集团、PSIM基金、Quadrant Management和Teampact Ventures等做出了重要贡献。

Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US.

自上一轮融资以来，Wandercraft 实现了显著增长，其在美国市场的商业扩张推动了收入增长十倍。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预测？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

全球数据

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

The Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft.

D轮融资之前，雷诺集团进行了战略合作并收购了少数股权，雷诺集团将利用其工业知识来扩大Wandercraft的外骨骼和机器人生产规模。

This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft’s quick development process and integrated with NVIDIA’s Isaac technologies.

这款工业级机器人据说仅用了40天就通过Wandercraft的快速开发流程完成，并集成了NVIDIA的Isaac技术，能够执行对体力要求高的任务。

Wandercraft co-founder and CEO Matthieu Masselin said: “The momentum we’ve achieved over the past few years is extraordinary.

Wandercraft联合创始人兼首席执行官马修·马塞兰表示：“我们在过去几年中取得的进展是非凡的。

“We’ve expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.”

“我们已经在全球范围内扩展，启动了关键的临床试验，准备将我们的个人外骨骼产品Eve商业化，并与雷诺集团达成了具有里程碑意义的合作。”

Wandercraft’s Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents.

Wandercraft的Atalante X目前被用于协助四大洲100多个康复中心的残疾人。

The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life.

Eve的引入旨在通过在日常生活中实现站立和行走来帮助轮椅使用者。

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

通过我们领先的行业洞察，为您的企业带来优势。

Medical Device Network Excellence Awards - Have you nominated?

医疗器械网络卓越奖——你提名了吗？

Nominations are now open for the prestigious

提名现已开放，迎接这一享有盛誉的